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Background. Antibiotic exposure and specimen volume are known to affect pathogen detection by culture. Here we assess their 
effects on bacterial pathogen detection by both culture and polymerase chain reaction (PCR) in children.
Methods. PERCH (Pneumonia Etiology Research for Child Health) is a case-control study of pneumonia in children aged 
1–59 months investigating pathogens in blood, nasopharyngeal/oropharyngeal (NP/OP) swabs, and induced sputum by culture and 
PCR. Antibiotic exposure was ascertained by serum bioassay, and for cases, by a record of antibiotic treatment prior to specimen 
collection. Inoculated blood culture bottles were weighed to estimate volume.
Results. Antibiotic exposure ranged by specimen type from 43.5% to 81.7% in 4223 cases and was detected in 2.3% of 4863 
controls. Antibiotics were associated with a 45% reduction in blood culture yield and approximately 20% reduction in yield from 
induced sputum culture. Reduction in yield of Streptococcus pneumoniae from NP culture was approximately 30% in cases and 
approximately 32% in controls. Several bacteria had significant but marginal reductions (by 5%–7%) in detection by PCR in NP/
OP swabs from both cases and controls, with the exception of S. pneumoniae in exposed controls, which was detected 25% less fre-
quently compared to nonexposed controls. Bacterial detection in induced sputum by PCR decreased 7% for exposed compared to 
nonexposed cases. For every additional 1 mL of blood culture specimen collected, microbial yield increased 0.51% (95% confidence 
interval, 0.47%–0.54%), from 2% when volume was ≤1 mL to approximately 6% for ≥3 mL.
Conclusions. Antibiotic exposure and blood culture volume affect detection of bacterial pathogens in children with pneumonia 
and should be accounted for in studies of etiology and in clinical management.
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Identifying the microbiological cause of pneumonia can help 
guide treatment and prevention strategies. However, this 
remains challenging for a variety of reasons, including subopti-
mal diagnostic accuracy of testing methods, difficulties obtain-
ing adequate blood specimen volumes in young children, and 
the administration of antibiotics prior to collection of diag-
nostic specimens [1–3]. Treatment with antibiotics prior to 
specimen collection has been shown to decrease detection of 
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potential bacterial pathogens from sterile body fluids in chil-
dren by culture and, to a lesser extent, by nucleic acid detec-
tion methods [4–8]. Less is known about the effect of antibiotic 
treatment on bacterial pathogen detection from nonsterile 
respiratory specimens, such as nasopharyngeal-oropharyngeal 
(NP/OP) swabs.
Blood volume has been reported as the most important fac-
tor influencing the sensitivity of blood cultures among patients 
with sepsis [3, 9], and each additional milliliter of blood cul-
tured has been associated with an increased microbial yield of 
up to 3% per specimen for adults [10]. Volume was previously 
assumed to be less important for children given the higher 
density of microorganisms typically found in their blood, but 
recent studies have confirmed that low-level bacteremia is more 
common than previously thought in pediatric patients [3], and 
increasing blood volume in children has been shown in several 
studies to increase bacterial yield [6, 11–14].
Here we aim to quantify the effect of antibiotic exposure and 
specimen volume on bacterial pathogen recovery from blood 
and respiratory specimens taken from children hospitalized 
with severe and very severe pneumonia, and to investigate the 
effect of key covariates of interest including age, human immu-
nodeficiency virus (HIV) infection status, chest radiograph 
(CXR) finding, disease severity, and research site on these 
estimates.
METHODS
The Pneumonia Etiology Research for Child Health (PERCH) 
study was a multicountry, case-control study of the etiology 
of severe pneumonia in children from developing countries 
[15]. Enrollment occurred for 24 months at each of 9 study 
sites located in 7 countries: Dhaka and Matlab, Bangladesh; 
Basse, The Gambia; Kilifi, Kenya; Bamako, Mali; Soweto, South 
Africa; Nakhon Phanom and Sa Kaeo, Thailand; and Lusaka, 
Zambia. Identification and selection of cases and controls have 
been described previously [16]. In brief, cases were hospitalized 
children aged 1–59 months with World Health Organization–
defined severe or very severe pneumonia [17]. Controls were 
randomly selected from the community and were frequen-
cy-matched to cases on month of enrollment and by the follow-
ing age groups: 1–5 months, 6–11 months, 12–23 months, and 
24–59 months. A second set of controls was frequency matched 
to HIV-infected cases at the 2 sites (Zambia and South Africa) 
with high HIV prevalence. Controls with respiratory tract 
illness were included only if they did not have case-defining 
severe or very severe pneumonia.
Blood, nasopharyngeal, and oropharyngeal (NP/OP) swabs, 
induced sputum (IS), and urine were collected from cases at 
study enrollment. A CXR was collected from cases as soon as 
possible after clinical evaluation and study enrollment and was 
reviewed by a trained panel using standardized guidelines for 
interpretation [18]. CXRs were considered normal if there was 
no consolidation or infiltrate present. Blood, NP/OP swabs, and 
urine were collected from controls at enrollment.
The study used standard culture methods to detect putative 
pneumonia pathogens from blood and respiratory specimens 
for the purpose of ascribing etiology [19]. A minimum 2-mL 
blood specimen was requested for culture for all participants 
weighing ≥3 kg, with a target volume of 3 mL. Culture bottles 
were weighed before and after inoculation, with the difference 
in weight multiplied by 1.05 (density of blood) to determine 
specimen volume in milliliters [20]. In the absence of strong 
evidence otherwise, organisms cultured from blood that met 
the a priori contaminant definition were considered as contam-
inants [19], and the identification of noncontaminant blood 
culture isolates was confirmed at the study reference laboratory. 
Enrollment blood specimens from cases and controls were also 
tested for Streptococcus pneumoniae by polymerase chain reac-
tion (PCR). Respiratory specimens were tested by multiplex 
PCR including 33 different bacterial and viral targets [19].
To detect exposure to antibiotics, a serum bioassay was per-
formed on sera collected from all cases and controls at enroll-
ment. A 6-mm filter paper disc was inoculated with 20 µL of 
serum and then placed on a Mueller-Hinton plate seeded with 
a 0.5 McFarland suspension of a sensitive Staphylococcus aureus 
strain (ATCC 25923). Any zone of inhibited bacterial growth 
around the disc after 18–24 hours of incubation was measured 
and recorded as evidence of serum antibiotic activity. Using 
urine, the same bioassay method was applied for a subset of 
cases in South Africa.
Study clinicians were encouraged to collect diagnostic spec-
imens prior to antibiotic administration whenever possible. 
Clinicians recorded the time of first antibiotic administration 
at the study facility and whether specimens had already been 
collected; additionally, the time and date of specimen collec-
tion and antibiotic administration were recorded. If the child 
was referred from another facility to the PERCH study facility, 
the parents were asked whether the child had received anti-
biotics at the referring facility. In some cases, documentation 
of the administration of antibiotics accompanied the child. 
Parents were also asked whether their children received anti-
biotics within the past 48 hours, or were receiving cotrimoxaz-
ole prophylaxis, but these self-reported data were not believed 
to be consistently reliable, were not good predictors of serum 
antimicrobial activity, and were therefore not included in the 
antibiotic exposure definition.
Cases were defined as having “antibiotic exposure prior to 
specimen collection” if they met any of the following criteria: 
had a positive serum antibiotic bioassay, received antibiotics at 
a referral facility (based on parental report or documentation), 
or received antibiotics at the study facility prior to the collection 
of specimens (assessed by clinician report and time/date cal-
culation). Controls were considered antibiotic exposed if they 
had a positive serum bioassay. Cases and controls whose results 
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were negative or not applicable for all of the exposure indicators 
were considered to not have antibiotic exposure. Those who did 
not meet any of the exposure criteria but had missing data for 1 
or more indicators were considered to have unknown exposure 
status.
Statistical Methods
Comparisons of binary outcomes were made using χ2 or Fisher 
exact test. Serum and urine antibiotic bioassay results were com-
pared using McNemar paired χ2 test. Multiple logistic regression 
and linear regression were used for adjusted analyses. Adjusted 
odds ratios (ORs) for laboratory outcomes in cases included 
site, age category, pneumonia severity, CXR status, and when 
relevant, blood culture volume, as covariates. Adjusted odds 
ratios for laboratory outcomes in controls included site, age cat-
egory, and HIV status as covariates. Percentage reduction was 
estimated using 1 minus the relative risk, which was calculated 
using the odds ratios. All P values are 2-sided. All analyses were 
done using STATA software version 13.0.
Ethical Considerations
The PERCH study protocol was approved by the institutional 
review board or ethical review committee at each of the study 
site institutions and at the Johns Hopkins Bloomberg School of 
Public Health. Parents or guardians of all participants provided 
written informed consent.
RESULTS
Between August 2011 and January 2014, PERCH enrolled 4232 
children hospitalized with severe (n  =  2862) or very severe 
(n = 1370) pneumonia and 5325 community controls. Nearly all 
(96.4%) cases received antibiotics at admission to the PERCH 
study facilities. The most commonly prescribed antibiotics at 
admission, either alone or in combination, were amoxicillin 
(1909/4709 [46.8%]), an aminoglycoside (2023 [49.6%]), and 
penicillin (1401 [34.3%]). Nearly half of cases (1833 [44.9%]) 
received combination therapy containing aminoglycoside with 
amoxicillin and/or penicillin. Among the 464 treated cases who 
did not receive amoxicillin or penicillin, 410 (88.4%) received 
ceftriaxone instead. With the exception of amoxicillin and 
amoxicillin/clavulanate, antibiotics were administered paren-
terally >95% of the time. Routine cotrimoxazole prophylaxis 
was reported in 79 of 902 (8.8%) cases and 138 of 940 (14.7%) 
controls in South Africa, and 76 of 611 (12.4%) of cases and 139 
of 686 (20.3%) controls in Zambia, the 2 sites with highest HIV 
prevalence.
Antibiotic Exposure Prior to Specimen Collection
Among cases, 18.3% of 4211 blood specimens, 25.3% of 4223 
NP/OP swabs, 71.7% of 3800 IS specimens, and 68.6% of 2388 
urine specimens were collected after antibiotic administration 
at the study facility. Blood was the first specimen obtained for 
91.3% of 4176 cases who had respiratory or urine samples col-
lected in addition to blood. The proportion of blood samples 
collected after antibiotic administration at the study facility 
varied by site, from 4.3% in Mali to 47.9% in Zambia (Table 1).
There was significant variation in the proportion of children 
receiving antibiotics at referral facilities prior to PERCH enroll-
ment. Three sites (Bangladesh, Kenya, and South Africa) had no 
facility that formally referred cases. In Zambia, 92.7% of cases 
visited another facility before coming to the study hospital and 
83.6% received antibiotics at that facility. At the 3 remaining 
sites, 1.3% (The Gambia), 11.9% (Mali), and 19.4% (Thailand) 
of cases received antibiotics at a referral facility (Table 1).
Serum antibiotic bioassay was performed on 94.1% of cases 
and 90.6% of controls; antibiotics were detected in 25.6% and 
2.3%, respectively, with the highest frequency of detection in 
South African cases (50.0%) (Table 1). Paired serum and urine 
bioassay results were compared in a subset of 476 participants 
(246 cases, 230 controls) from South Africa. Of these, 117 
(24.6%) serum specimens and 200 (42.0%) urine specimens 
were bioassay positive. Treating the urine bioassay as the refer-
ence standard, the sensitivity of the serum bioassay was 111 of 
200 (56%).
Of the 96.0% of cases and 91.3% of controls (range across 
sites, 90%–99% and 86%–96%, respectively; Supplementary 
Table 1) with data available to define “antibiotic exposure” prior 
to blood collection, 43.5% of cases and 2.3% of controls met 
the composite exposure definition (range across sites, 13.7%–
92.0% and 0.2%–4.8%, respectively; Table  1). NP/OP, IS, and 
urine specimens met the composite definition for antibiotic 
exposure in 48.8%, 80.4%, and 81.7% of cases, with variation 
by site (Table 2). Among cases, younger age (<12 months), an 
abnormal CXR (consolidation or infiltrate), and very severe 
(compared to severe) pneumonia were associated with antibi-
otic exposure prior to specimen collection (Table  3). Among 
controls, HIV infection was associated with increased odds of 
antibiotic exposure in South Africa and Zambia (Table 3).
Antibiotic Exposure and Detection of Organisms by Culture
The isolation of a noncontaminant organism from blood was 
significantly less frequent in cases exposed to antibiotics before 
specimen collection compared to those who received antibi-
otics after specimen collection (adjusted OR, 0.54; 95% con-
fidence interval [CI], .29–.98) after adjusting for site, blood 
volume, age category, abnormal CXR, and very severe (com-
pared to severe) pneumonia (Table  4). Associations did not 
vary significantly by bacteria (Table 4). Trends were consistent 
when limited to the subgroup of CXR-positive, HIV-uninfected 
cases, but did not reach statistical significance (Supplementary 
Table 2).
The culture yield of S. pneumoniae from NP swabs was sig-
nificantly reduced for both cases and controls pretreated with 
antibiotics, and this relationship was consistent when restricted 
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to the CXR-positive, HIV-uninfected cases and HIV-uninfected 
controls (Table 4; Supplementary Table 2). Among IS specimens 
collected from cases, antibiotic exposure was associated with 
reduced odds of growth of any isolate (Table 4). Among CXR-
positive, HIV-uninfected cases, the relationship was the same 
(Supplementary Table 2).
Antibiotic Exposure and Detection of Organisms by PCR
Detection of pneumococcus in whole blood by PCR was 
not significantly affected by antibiotic exposure (Table  5; 
Supplementary Table  3). For NP/OP specimens tested by 
Fast-track PCR, the mean number of positive bacterial targets 
detected in case specimens was higher in those with antibiotic 
exposure compared to those without (2.21 vs 2.05; P <  .001); 
this did not differ by CXR or HIV status. In contrast, con-
trols that were antibiotic exposed had fewer bacterial targets 
detected by NP/OP PCR than unexposed controls (1.18 vs 2.21; 
P <  .001), which also did not differ by HIV status. Cases and 
controls with antibiotic exposure before specimen collection 
were less likely to be positive by NP/OP PCR for S. pneumo-
niae, Haemophilus influenzae, or Moraxella catarrhalis (Table 5; 
Supplementary Table 3). For cases with NP samples positive by 
PCR for any of S. pneumoniae, H. influenzae, or M. catarrhalis, 
bacterial density was lower for those who were pretreated com-
pared to those who were not (Table 5; Supplementary Table 3). 
Cases were also more likely to have a S. pneumoniae PCR result 
above the density threshold (6.9 log10 copies/mL) associated 
with microbiologically confirmed pneumococcal pneumonia 
Table 2. Respiratory and Urine Specimens Collected After Exposure to Antibiotics Among Children Aged 1–59 Months Hospitalized With Pneumonia
Site
NP/OP Swabs Induced Sputum Urine
No.a Antibiotic Exposedb, No. (%) No.a Antibiotic Exposedb, No. (%) No.a Antibiotic Exposedb, No. (%)
All sites 4089 1994 (48.8) 3826 3075 (80.4) 3752 3066 (81.7)
Kenya 613 392 (40.7) 573 550 (96.0) 568 489 (86.1)
Gambia 578 89 (15.4) 556 134 (24.1) 586 402 (68.6)
Mali 670 176 (26.3) 558 467 (83.7) 522 453 (86.8)
Zambia
 HIV infected 102 91 (89.2) 98 98 (100.0) 101 100 (99.0)
 HIV uninfected 509 467 (91.8) 496 496 (100.0) 484 483 (99.8)
South Africa
 HIV infected 111 76 (68.5) 109 101 (92.7) 107 92 (86.0)
 HIV uninfected 784 474 (60.4) 770 719 (93.4) 689 545 (79.1)
Bangladesh 497 134 (27.0) 481 336 (69.9) 488 324 (66.4)
Thailand 223 94 (42.2) 185 174 (94.1) 206 177 (85.9)
Abbreviations: HIV, human immunodeficiency virus; NP/OP, nasopharyngeal/ oropharyngeal.
aOf those with specimen collected and known antibiotic administration status.
bAntibiotic exposure defined as any of the following: having a positive serum bioassay, received antibiotics at a referral facility, or received antibiotics at the study facility prior to the collec-
tion of enrollment blood specimen (assessed by clinician report and time/date calculation).
Table 1. Frequency of Blood Specimens Collected After Prior Exposure to Antibiotics Among Cases Aged 1–59 Months Hospitalized With Pneumonia and 












Any Facility Before 
Blood Collection 
(A or B) D. Serum Antibiotic Activity
Antibiotics Received Before Blood 
Collection (Any of A, B, or D for 
Cases and D Only for Controls)
Cases Cases Cases Cases Controls Cases Controls
All sites 4211a 769 (18.3) 4232 621 (14.7) 4232 1054 (24.9) 3995 1022 (25.6) 4864 110 (2.3) 4065 1767 (43.5) 4864 110 (2.3)
Kenya 634 183 (28.9) 634 0 (0.0) 634 183 (28.9) 562 73 (13.0) 777 22 (2.8) 585 238 (40.7) 777 22 (2.8)
The Gambia 622 33 (5.3) 638 8 (1.3) 638 41 (6.4) 579 43 (7.4) 616 1 (0.2) 571 78 (13.7) 616 1 (0.2)
Mali 674 29 (4.3) 674 80 (11.9) 674 105 (15.6) 672 129 (19.2) 700 19 (2.7) 670 174 (26.0) 700 19 (2.7)
Zambia
 HIV infected 103 36 (35.0) 100 82 (82.0) 103 89 (86.4) 99 36 (36.4) 75 8 (10.7) 101 90 (89.1) 75 8 (10.7)
 HIV uninfected 513 259 (50.5) 502 421 (83.9) 513 461 (89.9) 490 141 (28.8) 533 21 (3.9) 501 464 (92.6) 533 21 (3.9)
South Africa
 HIV infected 115 16 (13.9) 115 0 (0.0) 115 16 (13.9) 110 64 (58.2) 118 16 (13.6) 105 69 (65.7) 118 16 (13.6)
 HIV uninfected 805 119 (14.8) 805 0 (0.0) 805 119 (14.8) 768 375 (48.8) 764 8 (1.1) 719 411 (57.2) 764 8  (1.1)
Bangladesh 522 66 (12.6) 525 0 (0.0) 522 66 (12.6) 493 118 (23.9) 713 10 (1.4) 517 151 (29.2) 713 10 (1.4)
Thailand 223 28 (12.6) 222 43 (19.4) 223 51 (22.9) 222 43 (19.4) 568 5 (0.9) 223 69 (30.9) 568 5  (0.9)
Data are presented as No. (%).
Abbreviation: HIV, human immunodeficiency virus.
aNumbers for all sites exclude cases and controls with missing antibiotic exposure status (see Supplementary Table 1).
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threshold [21] if they were not exposed to antibiotics prior to 
specimen collection compared to those who were exposed. 
Trends were generally similar in controls, and when limited to 
the CXR-positive, HIV-uninfected cases and HIV-uninfected 
controls (Table  5; Supplementary Table  3). PCR detection of 
any bacteria, S.  pneumoniae, H.  influenzae, and M.  catarrh-
alis in IS specimens was significantly lower in exposed cases 
(Table 5). The same was true for CXR-positive, HIV-uninfected 
cases, except S. pneumoniae did not reach statistical significance 
in this group (Supplementary Table  3). Among cases with IS 
positive for S. pneumoniae, H. influenzae, or M. catarrhalis by 
PCR, reduced bacterial density was associated with antibiotic 
exposure (Table 5; Supplementary Table 3).
Blood Volume and Detection of Organisms by Blood Culture
Blood culture volumes were available for 3553 of 4232 (84.0%) 
specimens. Of the 679 specimens with missing volumes, 558 
(82.2%) were from South Africa. Mean blood culture volume 
was 2.05 mL (standard deviation [SD], 0.85 mL); only 12.4% of 
all blood culture specimens met the target volume of ≥3.0 mL 
(site range, 2.8% in Bangladesh to 33.1% in Mali; Table 6). Older 
age was associated with increased probability of a blood cul-
ture specimen volume ≥3.0 mL in The Gambia and Thailand 
(Table 6). An increase in blood culture yield was observed with 
greater blood culture volumes, from approximately 2% among 
specimens with ≤1 mL to >6% among specimens with >4 mL 
(Figure 1). In a univariate linear regression model, each addi-
tional 1  mL of blood collected was associated with a 0.51% 
(95% CI, 0.47%–0.54%) absolute increase in blood culture yield. 
Specimens with volume of at least 3 mL were significantly more 
likely to yield a blood culture pathogen compared to those with 
a volume of ≤1  mL (adjusted OR, 4.85; 95% CI, 1.24–18.99) 
after adjusting for site, age, CXR status, severity, and antibiotic 
exposure.
DISCUSSION
To our knowledge, this is the first study to evaluate the effect 
of antibiotic exposure across a range of specimen types and 
bacterial pathogens in a population of children hospitalized 
with severe or very severe pneumonia. Among cases and con-
trols, exposure reduced the detection of common pneumonia 
bacteria by culture and, to a lesser extent, PCR. After adjust-
ing for site and other relevant covariates, antibiotic exposure 
reduced blood culture yield of bacteria by approximately 45%. 
Results were similar for CXR-positive and HIV-uninfected 
cases and controls. Antibiotic exposure before specimen 
collection among hospitalized children was common in our 
study, with variation by study site and specimen type. Blood 
was almost always the first specimen collected and was col-
lected after exposure to antibiotics in approximately 40% 
of cases, while approximately 50%–80% of respiratory and 
urine specimens were collected after cases received antibiot-
ics. Antibiotic use among community controls was very low, 
with the exception of HIV-infected controls receiving routine 
cotrimoxazole prophylaxis. We also observed that increasing 
Table 3. Association of Hospitalized Case and Community Control Characteristics With Antibiotic Exposurea Prior to Blood Collection
Cases Controls
Antibiotic Exposure, No.b (%) AORc (95% CI) Antibiotic Exposure, No.b (%) AORc (95% CI)
Overall 1767 (43.5) 110 (2.3)
Age, mo
 1–5 768 (48.0) Ref 38 (2.6) Ref
 6–11 421 (48.2) 1.00 (.85–1.19) 28 (2.4) 0.95 (.58–1.55)
 12–23 309 (36.1) 0.61 (.51–.72) 29 (2.4) 0.93 (.57–1.52)
 24–59 179 (34.8) 0.58 (.47–.71) 15 (1.5) 0.56 (.31–1.03)
P value for variation <.001 .10
HIV statusd
 Negative/unknown 875 (71.7) Ref 29 (2.2) Ref
 Positive 159 (77.2) 1.33 (.94–1.89) 24 (12.4) 6.21 (3.53–10.92)
Chest radiograph findings
 Normal 547 (37.6) Ref … …
 Abnormal 801 (44.8) 1.35 (1.17–1.55)
Pneumonia severity … …
 Severe 1,044 (40.1) Ref
 Very severe 633 (51.1) 1.57 (1.37–1.79)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HIV, human immunodeficiency virus. Bold values are statistically significant at α = .05 level.
aAntibiotic exposure defined for cases as meeting any of the following criteria: having a positive serum bioassay, received antibiotics at a referral facility, or administered antibiotics at the 
study facility prior to the collection of specimens (assessed by clinician report and time/date calculation); for controls as having a positive serum bioassay. Participants with unknown anti-
biotic exposure data are excluded from these analyses.
bNumbers for all sites exclude cases and controls with missing antibiotic exposure status (see Supplementary Table 1).
cOdds ratios for cases are adjusted for age category, chest radiograph status, pneumonia severity, and study site as well as HIV status for relevant study sites (South Africa and Zambia only). 
Odds ratios for controls are adjusted for age category, HIV status, and research site.
dRestricted to sites with HIV prevalence >1.0% among cases (Zambia and South Africa).
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Table 4. Association of Antibiotic Exposure With Detection of Bacterial Organisms by Culture Among Participants Enrolled in the Pneumonia Etiology 
Research for Child Health (PERCH) Study
Specimen Antibiotic-Pretreateda Bacteria Isolated, No. (%) Adjusted ORb (95% CI)
Blood (cases) Any bacteriac
Yes (n = 1677)  61 (3.6) 0.54d (.29–.98)
No (n = 2167)  75 (3.5)
Any gram-positive bacteria
Yes (n = 1636)  10 (1.2) 0.26 (.10–.72)
No (n = 2092)  42 (2.0)
Streptococcus pneumoniae
Yes (n = 1625)  9 (0.6) 0.20 (.06–.70)
No (n = 2125)  33 (1.6)
Staphylococcus aureus
Yes (n = 1624)  8 (0.5) 0.36 (.03–4.33)
No (n = 2099)  7 (0.3)
Any gram-negative bacteria
Yes (n = 1656)  40 (2.4) 0.88 (.41–1.87)
No (n = 2124)  32 (1.5)
Hemophilus influenzae
Yes (n = 1623)  7 (0.4) 0.14 (.02–.99)
No (n = 2092)  13 (0.6)
Enterobacteriaceae
Yes (n = 1626)  10 (0.6) 1.22 (.29–5.04)
No (n = 2100)  8 (0.4)
Salmonella spp
Yes (n = 1630)  14 (0.9) 2.89 (.62–13.46)
No (n = 2096)  4 (0.2)
Nonfermenting gram-negative rods
Yes (n = 1625)  9 (0.6) 8.61 (.61–122.06)
No (n = 2095)  3 (0.1)
NP (cases) S. pneumoniae
Yes (n = 1924)  756 (39.3) 0.47 (.40–.56)
No (n = 1973)  1264 (64.1)
NP (controls) S. pneumoniae
Yes (n =  103)  48 (46.6) 0.39 (.26–.58)
No (n = 4712)  3290 (69.8)
IS (cases)e Any bacteria, excluding normal oropharyngeal flora
Yes (n = 2844)  1974 (68.5) 0.24 (.17–.33)
No (n = 751)  697 (92.8)
S. pneumoniae
Yes (n = 1444)  547 (37.9) 0.14 (.10–.20)
No (n = 511)  457 (89.4)
H. influenzae
Yes (n = 1713)  816 (47.6) 0.17 (.12–.24)
No (n = 555)  501 (90.3)
Moraxella catarrhalis
Yes (n = 1543)  646 (41.9) 0.21 (.13–.33)
No (n = 369)  315 (85.4)
S. aureus
Yes (n = 1201)  304 (25.3) 0.31 (.19–.50)
No (n = 122)  68 (55.7)
Other gram-negative rodsf
Yes (n = 897)  0 (0.0) …
No (n = 54)  0 (0.0)
Abbreviations: CI, confidence interval; IS, induced sputum; NP, nasopharyngeal; OR, odds ratio. Bold values are statistically significant at α = .05 level.
aAntibiotic exposure defined for cases as meeting any of the following criteria: having a positive serum bioassay, received antibiotics at a referral facility, or administered antibiotics at the 
study facility prior to the collection of specimens (assessed by clinician report and time/date calculation); for controls as having a positive serum bioassay. Participants with unknown antibiotic 
exposure data are excluded from these analyses.
bRelative odds of culture positivity (vs no growth of any organism) given antibiotic exposure, compared to those who are not pretreated. Odds ratios were adjusted for study site, pneumonia 
severity, chest radiograph (CXR) finding, blood culture specimen volume >3 mL, and age category. Respiratory specimens (NP, IS) in cases were adjusted for the same variables with the 
exception of blood specimen volume; NP in controls was adjusted for study site, age, and human immunodeficiency virus status.
cExcluding contaminants.
dThe crude odds ratio for the detection of any noncontaminant bacteria blood pathogen (antibiotic exposed vs unexposed) was 1.05 (95% CI, .75–1.49) due to a higher proportion of blood 
culture–positive specimens among the subset of cases with missing or uninterpretable CXR findings. After adjusting for CXR status, the OR is 0.92 (95% CI, .63–1.35). Further adjusting for, 
age, study site, pneumonia severity, and blood volume >3 mL produced the adjusted OR shown here.
eNo quality stringency criteria applied.
fOther gram-negative rods isolated from induced sputum includes Acinetobacter spp, Enterobacter aerogenes, Enterobacter cloacae, Pseudomonas species, and mixed gram-negative 
rods.
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Table 5. Association of Polymerase Chain Reaction Outcome by Antibiotic Exposure Status Among Children Aged 1–59 Months Enrolled in the Pneumonia 











Whole blood pneumococcal PCR—cases
Yes (n = 1559) 113 (7.3) 1.10 (.79–1.54) 2.81 (0.96) 0.13 (–.14 to .39)
No (n = 2122) 148 (7.0) 2.76 (0.98)
Whole blood pneumococcal PCR—controls
Yes (n = 106) 9 (8.5) 1.44 (.71–2.92) 2.58 (0.75) 0.22 (–.20 to .64)
No (n = 4596) 254 (5.5) 2.31 (0.61)
NP/OP respiratory PCR—cases
Any bacteria
Yes (n = 1894) 1747 (92.2) 0.74 (.56–.98) … …
No (n = 2022) 1896 (93.8)
Streptococcus pneumoniae
Yes (n = 1892) 1321 (69.8) 0.83 (.70–.98) 5.39 (1.27) –0.40 (–.52 to –.29)
No (n = 2021) 1502 (74.3) 5.94 (1.27)
S. pneumoniae above thresholdd
Yes (n = 1892) 144 (7.6) 0.43 (.33–.55) 7.33 (0.33) 0.06 (–.03 to .15)
No (n = 2021) 359 (17.8) 7.34 (0.35)
Haemophilus influenzae
Yes (n = 1892) 917 (48.5) 0.84 (.71–.99) 5.62 (1.24) –0.28 (–.41 to –.16)
No (n = 2018) 1186 (58.8) 5.93 (1.20)
Moraxella catarrhalis
Yes (n = 1892) 1223 (64.6) 0.83 (.70–.99) 5.17 (1.23) –0.32 (–.44 to –.21)
No (n = 2018) 1372 (68.0) 5.59 (1.12)
Staphylococcus aureus
Yes (n = 1892) 349 (18.5) 0.93 (.74–1.15) 5.34 (1.17) 5.34 (1.17)
No (n = 2021) 329 (16.3) 5.34 (1.17)
NP/OP respiratory PCR—controls
Any bacteria
Yes (n = 106) 91 (85.9) 0.40 (.22–.74) … …
No (n = 4596) 4398 (95.7)
S. pneumoniae
Yes (n = 106) 61 (57.6) 0.40 (.26–.59) 5.42 (1.20) –0.19 (–.46 to .08)
No (n = 4594) 3561 (77.5) 5.63 (1.11)
S. pneumoniae above thresholdd
Yes (n = 106) 106 (3.8) 0.44 (.16–1.23) 7.14 (0.15) –0.19 (–.46 to .08)
No (n = 4594) 365 (8.0) 7.25 (0.29)
H. influenzae
Yes (n = 106) 49 (46.2) 0.98 (.66–1.46) 5.30 (1.09) –0.19 (–.48 to .10)
No (n = 4589) 2391 (52.1) 5.60 (1.05)
M. catarrhalis
Yes (n = 106) 62 (58.5) 0.44 (.30–.67) 5.09 (1.33) –0.27 (–.52 to –.02)
No (n = 4589) 3416 (74.4) 5.48 (1.01)
S. aureus
Yes (n = 106) 15 (14.2) 1.08 (.61–1.02) 5.18 (1.21) 0.03 (–.50 to .55)
No (n = 4594) 623 (13.6) 5.00 (1.04)
Induced sputum PCR—cases
Any bacteria
Yes (n = 2791) 2496 (89.3) 0.52 (.32–.83) … …
No (n = 717) 688 (96.0)
S. pneumoniae
Yes (n = 2791) 1857 (66.5) 0.68 (.52–.89) 5.02 (1.18) –0.23 (–.35 to –.11)
No (n = 717) 559 (78.0) 6.15 (1.09)
H. influenzae
Yes (n = 2790) 1311 (47.0) 0.67 (.52–.85) 5.24 (1.16) –0.30 (–.44 to –.17)
No (n = 717) 497 (69.3) 6.05 (1.13)
M. catarrhalis
Yes (n = 2790) 1560 (55.9) 0.56 (.44–.72) 4.86 (1.30) –0.32 (–.46 to –.18)
No (n = 717) 538 (75.0) 5.86 (1.18)
S. aureus
Yes (n = 2791) 447 (16.0) 0.87 (.63–1.22) 5.01 (1.03) –0.07 (–.30 to .16)
No (n = 717) 99 (13.8) 5.23 (1.07)
Abbreviations: CI, confidence interval; NP/OP, nasopharyngeal/oropharyngeal; OR, odds ratio; PCR, polymerase chain reaction; SD, standard deviation. Bold values are statistically significant 
at α = .05 level.
aAntibiotic exposure defined for cases as any of the following: having a positive serum bioassay, received antibiotics at a referral facility, or received antibiotics at the study facility prior to the 
collection of specimens (assessed by clinician report and time/date calculation); Antibiotic exposure for controls is defined as having a positive serum bioassay. Participants with unknown 
antibiotic exposure status are excluded from analyses.
bRelative odds of pathogen detection given antibiotic exposure, compared to those who were not pretreated. Odds ratios are adjusted for study site, pneumonia severity, chest radiograph 
status, and age. NP/OP outcomes in controls are adjusted for study site, human immunodeficiency virus infection status, and age.
cFold-difference in mean log10 transformed PCR density (copies/mL) for pretreated compared to non-pretreated individuals, among those PCR positive.
dAbove PCR density threshold (6.9 log10 copies/mL) associated with case status [21].
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blood volume was associated with greater recovery of blood 
pathogens by culture.
Our findings are consistent with a study from rural Kenya 
that found that recent antibiotic use (measured by plasma 
microbial activity) in children <13  years of age reduced 
blood culture yield by 62%–73% in patients with severe or 
fatal disease, and greater blood volume yielded higher bac-
terial detection by culture [6]. Similarly in Thailand, inci-
dence rates of hospitalized pneumococcal bacteremia among 
children aged <5  years were 63% higher when adjusted for 
antibiotic use defined by serum antimicrobial activity [4]. 
Staphylococcus aureus, Enterobacteriaceae, and nonfermenting 
gram-negative rods were not affected by antibiotic exposure in 
our study, which is expected given that most first-line antibiot-
ics do not have activity against these classes of bacteria.
For NP culture specimens, antibiotic exposure reduced detec-
tion of pneumococcus by culture by approximately 30% in cases 
and controls, with a more modest reduction in detection (by 
approximately 5%–7%) of bacterial pathogens by PCR. These 
findings are similar to those in a study of an elderly population 
in Finland where detection of pneumococcus was significantly 
reduced for NP culture and showed a nonsignificant trend 
toward reduction by PCR [22]. The reduction in detection by 
PCR attributable to antibiotic exposure was greater for controls 
than cases, which could be due to the lower bacterial densities 
in controls. On average, IS specimens were collected several 
hours and up to a day following blood and NP/OP swabs, which 
could explain the greater effect of antibiotic exposure on detec-
tion of pathogens in IS, particularly for children whose source 
of antibiotic exposure occurred at hospital admission.
Our analyses have several limitations. Most importantly, 
there was potential for misclassification of antibiotic exposure 
status. Antibiotic type, dose, and timing relative to specimen 
collection could all be expected to impact serum antimicrobial 
activity, potentially resulting in misclassification, and could not 
be taken into account in our definition. Although the timing 
between administration and specimen collection at the study 
facility was available, we felt that the application of a time cutoff 
for exposure would be arbitrary and therefore considered any 
specimen that was collected following antibiotic administration 
to be exposed. Serum bioassay was selected over urine to eval-
uate presence of antibiotics because urine was >4 times more 
likely than serum to be collected after antibiotic administration. 
However, serum has been shown to be less sensitive than urine 
for this application [23–25], and the 56% sensitivity we observed 
for serum compared to urine is the same as reported elsewhere 
[23]. Another weakness of the serum bioassay is that given the 
half-life of antibiotics in the blood, it may only reliably detect 
antimicrobial exposure within the past 8 hours [26] and, as a 
result, receipt of antibiotics prior to this time frame may result in 
sterilization of the blood while being undetectable. In addition 



























































































































































































































































































































































































































































































































































































































































































































































































































































































by London School of Hygiene & Tropical Medicine user
on 26 January 2018
S376 • CID 2017:64 (Suppl 3) • Driscoll et al
antibiotic exposure in that cases with bacterial pneumonia may 
have been more ill and therefore more likely to have received 
antibiotic treatment prior to admission. If so, our estimates of 
the effect of antibiotic exposure on bacterial recovery would be 
underestimated.
Specimens identified as “not exposed to antibiotics” may 
also have been misclassified as antibiotics administered by the 
parents were not captured in our definition. If so, our findings 
would again be biased toward the null, and the true impact of 
exposure would therefore be of a greater magnitude than what 
is reported here. The level of misclassification might vary by 
study site, which may explain some site differences, as might 
the exclusion of participants missing antibiotic exposure sta-
tus, which also varied by site. Finally, small numbers of positive 
blood cultures limited our ability to analyze pathogen-specific 
associations with antibiotic exposure, and the large proportion 
of missing blood culture volumes from South Africa reduced the 
precision of the estimate of the impact of blood culture volume 
on positivity for this site.
Despite these limitations, our data reveal consistent and 
statistically significant reductions in the detection of bacte-
rial pathogens in blood and respiratory specimens of children 
associated with exposure to antibiotics prior to specimen col-
lection and low blood volume. Because few bacterial pneu-
monias are bacteremic, a reduction in the sensitivity blood 
culture worsens the already existing challenge of isolating an 
etiologic agent from blood. Clinicians managing the care of 
pneumonia patients and researchers evaluating the relative 
contribution of bacterial pathogens to the etiology of these 
syndromes should make efforts to draw blood culture vol-
umes ≥3  mL, collect specimens prior to antibiotic adminis-
tration, obtain accurate measurements of antibiotic exposure, 
and interpret test results in accordance with blood volume and 
prior antibiotic exposure. Failure to do so may overestimate 
the proportion of antibiotic-resistant organisms and underes-
timate the relative contributions of antibiotic-sensitive patho-
gens, such as S. pneumoniae, H. influenzae, and M. catarrhalis, 
to pneumonia etiology.
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